Gynecologic Oncology | Specialty

Rucaparib Significantly Improves PFS Over Chemo in Later-Line, BRCA+ Ovarian Cancer

December 21st 2020

December 21, 2020 - Rucaparib was found to result in a statistically significant improvement in progression-free survival compared with chemotherapy in patients with BRCA-mutant ovarian cancer who had previously received 2 or more lines of chemotherapy.

Weighing Risks and Benefits Is Critical With Second-Line Maintenance PARP Inhibition in Ovarian Cancer

December 19th 2020

Allison M. Puechl, MD, discusses the role of second-line maintenance therapy in patients with recurrent ovarian cancer and considerations that may limit the accessibility of PARP inhibitors in this space.

Pembrolizumab/Lenvatinib Combo Improves Survival, Responses Over Chemo in Advanced Endometrial Cancer

December 16th 2020

December 16, 2020 - Pembrolizumab/lenvatinib has significantly improved survival and responses compared with chemotherapy in patients with advanced endometrial cancer who have received previous systemic treatment.

Dr. Matulonis on the Need to Improve Immunotherapy Responses in Gynecologic Cancers

December 8th 2020

Ursula A. Matulonis, MD, discusses the need to improve responses to immunotherapy among patients with recurrent gynecologic cancers.

BLA Submission for Balstilimab in Recurrent/Metastatic Cervical Cancer Delayed

December 4th 2020

December 4, 2020 - The completion of the biologics license application for balstilimab in the treatment of patients with recurrent or metastatic cervical cancer has been delayed to the first half of 2021.

Huntsman Homes in on the Integration of Precision Medicine in Oncology

December 3rd 2020

In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Survivin-Targeted T-Cell Therapy Shows Durable Activity in Advanced Recurrent Ovarian Cancer

December 3rd 2020

December 3, 2020 — The survivin-targeted T-cell therapy DPX-Survivac, when used in combination with intermittent low-dose cyclophosphamide, prolonged clinical benefit with promising tolerability in patients with recurrent, advanced platinum-sensitive and -resistant ovarian cancer.

Need for Genetic Testing Becomes More Pronounced in Breast, Gynecologic Cancers as Targeted Approaches Abound

December 2nd 2020

Lan G. Coffman, MD, PhD, discusses the role of genetic testing in breast and gynecologic cancers and the many advances made with targeted therapies.

Novel Cancer Vaccine DSP-7888 Proceeds to Phase 2 in Ovarian Cancer, First Patient Dosed

December 2nd 2020

December 2, 2020 - The novel immunotherapeutic vaccine DSP-7888, in combination with pembrolizumab, has been dosed in the first patient with platinum-resistant ovarian cancer.

Marvels in Medicine: Dr. Karlan on Creating Continuous Quality Improvement in Gynecologic Oncology

November 30th 2020

In our exclusive interview, Dr. Karlan discusses pivotal moments in her career as a gynecologic oncologist, the challenges of forging a name for herself, and future directions for the field.